GlassScriptPhysician profile
Brian Hom
NPI 1841795663
$9,750.54
in general payments reported to CMS, 2019-2025
19 companies · $2,660 in 2025
The $2,660 reported for 2025 was more than what 83% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,017 · 2023: $3,527 · 2024: $1,548 · 2025: $2,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,271 · Travel and Lodging: $2,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,270.69 |
| Travel and Lodging | $2,463.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,342.37 | 2022-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Pain Management |
| Medtronic, INC. | $1,737.99 | 2022-2024 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Biotronik Nro, INC. | $1,560.61 | 2024-2025 | Prospera |
| Abbott Laboratories | $460.93 | 2025 | Proclaim |
| Abbvie INC. | $372.60 | 2023-2025 | |
| Spr Therapeutics, INC | $266.27 | 2023-2024 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $179.38 | 2024-2025 | Belbuca, Xtampza |
| Stryker Corporation | $176.01 | 2025 | Mild Device Kit, Optablate |
| Vertos Medical, INC. | $171.22 | 2023 | Mild Device Kit |
| Nevro Corp. | $124.71 | 2023 | Senza |
| Tersera Therapeutics LLC | $114.95 | 2023-2025 | Prialt |
| Pfizer INC. | $59.00 | 2024-2025 | |
| Lundbeck LLC | $47.73 | 2024 | Vyepti |
| Azurity Pharmaceuticals, INC. | $35.52 | 2023-2024 | Horizant, Horizant |
| Scilex Pharmaceuticals INC. | $22.99 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $22.89 | 2023 | Trudhesa |
| Mml US, INC. | $22.01 | 2025 | Reactiv8 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.05 | 2023 | Relistor |
| Ibsa Pharma INC. | $16.31 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.